{
 "PrintNo":"A9662","Version":"A","Session":2023,"Chamber":"ASSEMBLY","BillType":"Assembly",
 "Published":"2024-03-27T08:59:47.570124Z","Status":"IN_ASSEMBLY_COMM","Committee":"Insurance",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2024-05-13","Committee":"Insurance"}],
 "Actions":[
  {"Text":"REFERRED TO INSURANCE","Date":"2024-03-27","Chamber":"ASSEMBLY"},
  {"Text":"AMEND AND RECOMMIT TO INSURANCE","Date":"2024-05-13","Chamber":"ASSEMBLY"},
  {"Text":"PRINT NUMBER 9662A","Date":"2024-05-13","Chamber":"ASSEMBLY","Version":"A"}
 ],
 "Sponsors":[{"ID":484,"Name":"David Weprin","Short":"WEPRIN"}],
 "Title":"Relates to capping cost sharing for antiviral COVID-19 therapeutics",
 "Summary":"Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.",
 "LawSection":"Insurance Law","LawCode":"Amd §§3216, 3221 & 4303, Ins L; amd §365-a, Soc Serv L",
 "ActClause":"AN ACT to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics",
 "SameAsPrintNo":"S8367-2023"
}